Clinical trials: Liver Diseases, Alcoholic
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Comparative and Additive Diagnostic Performance of Magnetic Resonance Elastography (MRE) and Corrected-T1 (cT1) for Fibrosis and Inflammation in Nonalcoholic Steatohepatitis (NASH) Using Histology As Reference
This pilot study will evaluate conventional and investigational MR imaging and spectroscopic sequences and collect data to help plan more definitive future studies.
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Liver Fibroses, Liver Inflammation
- Trial name
- NCT04389593
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Non-Alcoholic Fatty Liver Disease
Effects of Time-restricted Hypocaloric Diet in Patients with NAFLD
The effects of a time-restricted hypocaloric Mediterranean type diet compared to a conventional hypocaloric Mediterranean type diet on blood glucose metabolism and liver steatosis in people with non-alcoholic fatty liver disease…
- Trial name
- NCT05866744
- Testing
- Early Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet, Late Time-Restricted Feeding Plus Hypocaloric Mediterranean Diet, Hypocaloric Mediterranean Diet Without Time Restriction In Feeding
- Where
- 2 sites in Greece
- Volunteers
- 59 people
- Sponsor
- Agricultural University of Athens
Non-Alcoholic Steatohepatitis (NASH)
Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
The primary objective of this study is to evaluate the safety and tolerability of GS-4997 (selonsertib [SEL]) alone or in combination with simtuzumab (SIM) in adults with nonalcoholic steatohepatitis (NASH) and fibrosis stages…
- Trial name
- NCT02466516
- Testing
- SEL, SIM
- Where
- 28 sites in United States, Canada
- Volunteers
- 72 people
- Sponsor
- Gilead Sciences
T2DM (Type 2 Diabetes Mellitus), Fatty Liver
Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study
The primary objective of this study is to investigate the change in Alanine Aminotransaminase (ALT) in patients with Type 2 Diabetes Mellitus (T2DM) initiating Sodium Glucose Cotransporter 2 (SGLT2) inhibitors, liraglutide, or…
- Conditions
- T2DM (Type 2 Diabetes Mellitus), Fatty Liver, NAFLD
- Trial name
- ALT (NCT03233178)
- Testing
- Non-interventional
- Where
- Canada
- Volunteers
- 4,000 people
- Sponsor
- LMC Diabetes & Endocrinology Ltd.
Obesity
Interventional Strategy in Tackling Emerging Non-alcoholic Fatty Liver Disease in Childhood Obesity
The goal of this clinical trial is to investigate the effects of tocotrienol-rich fraction vitamin E supplementation on liver enzymes in overweight and obese children with non-alcoholic fatty liver disease as compared to placebo.
- Trial name
- NCT05905185
- Testing
- Tocotrienol-rich fraction vitamin E (TRF)
- Where
- Malaysia
- Volunteers
- 29 people
- Sponsor
- National University of Malaysia
Nonalcoholic Fatty Liver Disease
Effect of Iron Depletion by Phlebotomy Plus Lifestyle Changes vs. Lifestyle Changes Alone on Liver Damage in Patients With Nonalcoholic Fatty Liver Disease With Increased Iron Stores
Patients will be randomized to lifestyle changes alone or lifestyle changes associated with iron depletion. Iron depletion will be achieved by removing 350 cc of blood every 10-15 days according to baseline hemoglobin values and…
- Trial name
- NCT00658164
- Testing
- Iron depletion treatment
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Metabolic Syndrome, Obesity
Potential Beneficial Effects of Resveratrol
We want to investigate whether the food supplement resveratrol is able to counteract the detrimental effects of obesity.
- Trial name
- NCT01150955
- Testing
- Resveratrol
- Where
- Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Nonalcoholic Steatohepatitis (NASH)
Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients
We conducted a 3-month, randomized, single-blind study in 102 Egyptian NASH patients who were divided into three groups; group 1 included 34 patients received Vit.
- Trial name
- NCT04977661
- Testing
- Vitamin E, Ursodeoxycholic acid, Pentoxifylline
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Kafrelsheikh University
Non-alcoholic Steatohepatitis
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
Semaglutide is a medicine studied in patients with non-alcoholic steatohepatitis (NASH), as it may improve liver damage. Participants will either get semaglutide or placebo (a dummy medicine) - which treatment participants get is…
- Trial name
- NCT03987451
- Testing
- Semaglutide
- Where
- 38 sites in United States, France and 3 more
- Volunteers
- 71 people
- Sponsor
- Novo Nordisk A/S
NAFLD, Liver Fibroses
Liver Damage and Cardiometabolic Disorders in NAFLD
Liver fibrosis is the most important prognostic factor in patients with non-alcoholic factor disease. Clinical and biological condition, as diabetes or mutation for PNPLA3, are well known factors associated with liver fibrosis…
- Conditions
- NAFLD, Liver Fibroses, Cardiovascular Diseases, Cardiovascular Risk Factor
- Trial name
- PLINIO (NCT04036357)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- University of Roma La Sapienza
Nonalcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis
Safety Evaluation of IV Tc 99m Tilmanocept and Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH
This is a prospective, open-label, multicenter, safety, comparative study of IV administered Tc99m-tilmanocept and unfiltered Tc99m sulfur colloid in the detection of and assessment of three dimensional tessellation localization…
- Trial name
- NCT03332940
- Testing
- Tc 99M Sulfur Colloid, Tc99m-tilmanocept
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Navidea Biopharmaceuticals
Chronic Pancreatitis, Inflammatory Bowel Diseases
Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study
This is a prospective, descriptive, observational research study designed to observe and document the clinical practice by domain experts, and how the knowledge of new findings that are published in the medical literature affect…
- Conditions
- Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- GREAT1 (NCT04306939)
- Testing
- venipuncture, Questionnaires, Additional Sample Collections
- Where
- United States
- Volunteers
- 120,000 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Alcoholic Hepatitis
Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis
This multicenter, randomized, double blinded, placebo-controlled clinical trial is focused on novel treatments for severe alcoholic hepatitis (AH), a life-threatening stage of alcoholic liver injury that has a short-term…
- Trial name
- AlcHepNet (NCT04072822)
- Testing
- Anakinra and Zinc, Prednisone
- Where
- 10 sites in United States
- Volunteers
- 147 people
- Sponsor
- Indiana University
Fibrosis of Liver
Establishment of NAFLD Cohort and Development of Fibrosis Markers
This study is designed for establishment of non-alcoholic fatty liver disease patients cohort to development of markers to predict histologic progression of liver fibrosis.
- Trial name
- NAFLD (NCT02206841)
- Testing
- Liver biopsy, ARFI, SWE
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Seoul National University Boramae Hospital
NASH - Nonalcoholic Steatohepatitis
Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis
Participants meeting study entry criteria are randomized with equal probability to one of two study groups: (1) Lifestyle modification or (2) Vertical Sleeve Gastrectomy (VSG) with Iifestyle modification, followed for 12 months.
- Trial name
- NCT03587831
- Testing
- Vertical Sleeve Gastrectomy, Lifestyle Modification Counseling
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Minnesota
Non-alcoholic Fatty Liver Disease
Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH
The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated.
- Trial name
- SKYLINE (NCT06104319)
- Testing
- GSK4532990
- Where
- 14 sites in United States
- Volunteers
- 61 people
- Sponsor
- GlaxoSmithKline
COVID-19
Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection
A prospective, longitudinal, observational cohort study looking at patients following COVID-19 disease using multi-parametric magnetic resonance imaging (MRI) to assess the degree and prevalence of organ injury.
- Trial name
- COVERSCAN (NCT04369807)
- Testing
- Outpatient MRI
- Where
- 2 sites in United Kingdom
- Volunteers
- 693 people
- Sponsor
- Perspectum
Fatty Liver
Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)
Background: Non-alcoholic fatty liver disease (NAFLD) is a common cause of abnormal liver tests. It is closely linked to health problems like obesity and diabetes.
- Trial name
- NCT02363309
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Fatty Liver, Insulin Resistance
Insulin Resistance in Non-alcoholic Fatty Liver Disease
The purpose of this study is to determine whether nonalcoholic fatty liver disease (NAFLD) is associated with altered peripheral and hepatic insulin sensitivity and to investigate potential mechanisms underlying insulin…
- Trial name
- NCT00252499
- Testing
- rosiglitazone, fenofibrate
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
Non-Alcoholic Fatty Liver Disease
Effect of Molecular Hydrogen in Patients With NAFLD
Molecular hydrogen H2 acts as antioxidant which selectively reduces cytotoxic harmful reactive oxygen species ROS and concomitantly acts as biological messenger, which mediates several signaling pathways that play cytoprotective…
- Trial name
- EMoHyNAFLD (NCT05325398)
- Testing
- HRW drink, HRW Natural Health Products Inc., Made in Vancouver, Canada
- Where
- Slovakia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Comenius University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.